The goal of this observational study is to evaluate hematological abnormalities among patients with systemic lupus erythematosus (SLE) admitted to a tertiary care center in Nepal. The main question it aims to answer is: \- What are the types and frequencies of hematological abnormalities seen in hospitalized SLE patients in Nepal? The study retrospectively reviews medical records of SLE patients admitted between April 2018 and March 2023 to collect data on hematologic parameters, demographic profiles, clinical manifestations.
Study Type
OBSERVATIONAL
Enrollment
99
Patan Hospital
Lalitpur, Bagmati Province, Nepal
Percentage of patients with hematological abnormalities
Anemia was defined as a Hb of less than 13 g/dL in males and less than 12 g/dL in females. Leukopenia was defined as a WBC of less than 4000 per cubic millimeter (cu.mm). Thrombocytopenia was defined as a platelet count of less than 100,000 per cubic millimeter. Lymphopenia and neutropenia were defined as absolute lymphocyte count less than 1500 per cu.mm and absolute neutrophil count less than 1800 per cu.mm.
Time frame: Baseline at the time of hospital admission. (Cross-sectional)
Percentage of SLE patients with mucocutaneous involvement
Proportion of patients exhibiting at least one mucocutaneous manifestation (malar rash, discoid rash, alopecia, or oral ulcers) based on physician-documented diagnosis following 2019 EULAR/ACR criteria.
Time frame: Through study completion from 2019 January to 2023 December.
Percentage of SLE patients with pericarditis
Proportion of patients exhibiting pericarditis based on physician-documented diagnosis following 2019 EULAR/ACR criteria.
Time frame: Through the study completion from 2019 January to 2023 December.
Percentage of SLE patients with respiratory involvement
Proportion of patients exhibiting respiratory involvement based on physician-documented diagnosis following 2019 EULAR/ACR criteria.
Time frame: Through the study completion from 2019 January to 2023 December.
Percentage of SLE patients with gastrointestinal involvement
Proportion of patients exhibiting gastrointestinal involvement based on physician-documented diagnosis following 2019 EULAR/ACR criteria.
Time frame: Through the study completion from 2019 January to 2023 December.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Percentage of SLE patients with kidney involvement
Proportion of patients exhibiting kidney involvement based on physician-documented diagnosis following 2019 EULAR/ACR criteria.
Time frame: Through the study completion from 2019 January to 2023 December.
Percentage of SLE patients with musculoskeletal involvement
Proportion of patients exhibiting musculoskeletal involvement based on physician-documented diagnosis following 2019 EULAR/ACR criteria.
Time frame: Through the study completion from 2019 January to 2023 December.
Percentage of SLE patients with neurological involvement
Proportion of patients exhibiting neurological involvement based on physician-documented diagnosis following 2019 EULAR/ACR criteria.
Time frame: Through the study completion from 2019 January to 2023 December.